Back Talk

Focus turns to future after Right to Try Act passes

Congress has finally passed the Right to Try Act, but does it go far enough?

Is it time for pharma ad agencies to reboot?

As global advertisers cut their spending, should the agency world take a hard look in the mirror?

Drugs' value to patients eclipsed by price tags

Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.

Will PBMs take heat for high drug prices?

PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?

Can a nonprofit make generics great again?

Acquisitions that were applauded a few years ago, such as Teva's purchase of Allergan's generic business, now look like lemons.

Did Congress just kill the Orphan Drug Act?

By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first time.

We Save Lives While Our Critics Complain

In his first press conference as president-elect, Donald Trump insisted pharma was "getting away with murder" due to expensive drug prices.

Gottlieb Eyes Prices, Not Lives

It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.

Who's Getting Rich in Healthcare?

Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?

AI Drug Design Could Save Lives

AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.